SEC Form 4	
------------	--

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287									
Estimated average b	Estimated average burden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						0000			mesune			01 1040							
1. Name and Address of Reporting Person [*] Quimi Daphne					2. Issuer Name and Ticker or Trading Symbol Century Therapeutics, Inc. [IPSC]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Quini Dapine													X Direct	or		10% Ov	vner		
(Last) (First) (Middle) 3675 MARKET STREET						3. Date of Earliest Transaction (Month/Day/Year) 10/01/2022								Office below	r (give title)		Other (s below)	pecify	
					4 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
				- ···	The information of the of onginal filed (working ay fear)								Line)						
(Street) PHILADELPHIA PA 19104													X Form filed by One Reporting Person						
PHILADELPHIA PA 19104			-									Form filed by More than One Reporting Person							
(City)	(S	tate)	(Zip)																
Table L. Non Derivative Securities Acquired Disposed of or Beneficially Owned																			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,			Code (Instr. 5)			ed (A) or str. 3, 4 an	Benefic	es	Form (D) o	n: Direct r Indirect	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) oi (D)	^r Price	Reporte Transac (Instr. 3	d tion(s)			(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any			Date,	4. Transaction Code (Instr. 8) (A) or Dispos of (D) ((A) or Dispos of (D) (3, 4 an			ive ies ed ed nstr.	Expiration Date e (Month/Day/Year) s t str.			7. Title and Amoun of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal	ble	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$9.89	10/01/2022			A		39,744		(1)		10/01/2032	Common Stock	39,744	\$0	39,74	4	D		

Explanation of Responses:

1. Century Therapeutics, Inc. (the "Company") issued Ms. Quimi stock options (the "Options") in connection with her appointment as a director. The Options vest in equal monthly installments over 36 months subject to Ms. Quimi's continued service to the Company and are issued pursuant to the Company's 2021 Equity Incentive Plan.

/s/ Michael Diem, Attorney-in-Fact <u>10/03/2022</u>

.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.